Biogen will integrate Alcyone's team and divest the remaining assets into Neela Therapeutics as part of its $85 million ...

SaveHealth reports on advancements in dementia medications, highlighting new treatments that modify disease progression and ...

BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth ...

The postpartum depression marketing authorisation in the EU follows approvals for the drug in the US and the UK over the past ...

Eli Lilly's strong Q2 results, raised guidance, and robust demand for tirzepatide reinforce confidence in its commercial ...

In 2020, the Illinois Lottery launched a specialty Instant Lottery ticket called The End of Alzheimer’s Begins With Me, designating 100 percent of its profits to the Alzheimer’s Association, Illinois ...

The Alzheimer’s Association will host a community presentation Sept. 22 in Laredo to share the latest developments in research and treatment options for Alzheimer’s disease.

One of neurologist Anelyssa D’Abreu’s least favorite tasks is giving her patients a dreaded diagnosis: early-stage ...

New Alzheimer’s drugs known as anti-amyloid therapies may slow disease progression—but they also carry serious risks, ...

Detailed price information for Algernon Pharmaceuticalsinc (AGN-CN) from The Globe and Mail including charting and trades.

Retro Biosciences is set to run a clinical trial for an aging drug designed to reverse Alzheimer's, its CEO Joe Betts-LaCroix ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen, with a price target of $118.00. The company’s shares closed yesterday at $141.62. Take advantage of ...